Published in PLoS One on October 06, 2011
Comparative pathology of smallpox and monkeypox in man and macaques. J Comp Pathol (2012) 0.87
Efficacy of tecovirimat (ST-246) in nonhuman primates infected with variola virus (Smallpox). Antimicrob Agents Chemother (2013) 0.85
Primary human macrophages serve as vehicles for vaccinia virus replication and dissemination. J Virol (2014) 0.83
Comparison of host cell gene expression in cowpox, monkeypox or vaccinia virus-infected cells reveals virus-specific regulation of immune response genes. Virol J (2013) 0.78
Vaccinia virus Transmission through Experimentally Contaminated Milk Using a Murine Model. PLoS One (2015) 0.75
Pharmacokinetic and pharmacodynamic modeling to determine the dose of ST-246 to protect against smallpox in humans. Antimicrob Agents Chemother (2012) 0.75
Susceptibility of Marmosets (Callithrix jacchus) to Monkeypox Virus: A Low Dose Prospective Model for Monkeypox and Smallpox Disease. PLoS One (2015) 0.75
Smallpox as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA (1999) 7.96
Inhibition of viral replication by interferon-gamma-induced nitric oxide synthase. Science (1993) 4.80
Th1-type immunity is incompatible with successful pregnancy. Immunol Today (1997) 3.71
New drug and biological drug products; evidence needed to demonstrate effectiveness of new drugs when human efficacy studies are not ethical or feasible. Final rule. Fed Regist (2002) 3.07
The Pathological Anatomy and Histology of Variola. J Med Res (1904) 2.70
Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells. Am J Pathol (2003) 2.66
The pathology of experimental aerosolized monkeypox virus infection in cynomolgus monkeys (Macaca fascicularis). Lab Invest (2001) 2.38
Exploring the potential of variola virus infection of cynomolgus macaques as a model for human smallpox. Proc Natl Acad Sci U S A (2004) 2.36
Smallpox and pan-orthopox virus detection by real-time 3'-minor groove binder TaqMan assays on the roche LightCycler and the Cepheid smart Cycler platforms. J Clin Microbiol (2004) 1.77
The morbid anatomy of smallpox. Doc Med Geogr Trop (1952) 1.47
A successful eradication campaign. Global eradication of smallpox. Rev Infect Dis (1983) 1.44
Histopathogenesis of mousepox. I. Respiratory infection. Br J Exp Pathol (1962) 1.12
Sex hormones and pregnancy in rheumatoid arthritis and systemic lupus erythematosus. Ann N Y Acad Sci (1999) 1.11
Sex hormones and autoimmunity. Immunol Lett (2010) 1.11
Gender differences in the development and function of the immune system. J Adolesc Health (2002) 1.10
Type 1 and type 2 cytokines in antiviral defense. Vet Immunol Immunopathol (1998) 1.06
Smallpox: emergence, global spread, and eradication. Hist Philos Life Sci (1993) 1.05
The eradication of smallpox. Prog Med Virol (1977) 0.95
The global eradication of smallpox. Med J Aust (1980) 0.84
The inflammatory and immune response to mousepox (infectious ectromelia) virus. Acta Virol (1994) 0.83
An epidemiological analysis of the 1971 smallpox outbreak in Aralsk, Kazakhstan. Crit Rev Microbiol (2003) 0.82
Some General Considerations on the Pathology of Smallpox. Public Health Pap Rep (1905) 0.80
Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med (2005) 6.77
Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA (2002) 6.59
Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature (2003) 6.35
Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. Am J Pathol (2003) 4.67
Exotic emerging viral diseases: progress and challenges. Nat Med (2004) 4.54
Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet (2010) 4.52
Proposal for a revised taxonomy of the family Filoviridae: classification, names of taxa and viruses, and virus abbreviations. Arch Virol (2010) 3.77
Effective post-exposure treatment of Ebola infection. PLoS Pathog (2007) 3.69
Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature (2004) 3.65
Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. Lancet (2003) 3.57
Panmicrobial oligonucleotide array for diagnosis of infectious diseases. Emerg Infect Dis (2007) 3.51
Middle East respiratory syndrome coronavirus infection in dromedary camels in Saudi Arabia. MBio (2014) 3.49
An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge. J Virol (2005) 3.36
Mechanisms underlying coagulation abnormalities in ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event. J Infect Dis (2003) 3.33
Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment. Lancet (2006) 3.15
Comprehensive panel of real-time TaqMan polymerase chain reaction assays for detection and absolute quantification of filoviruses, arenaviruses, and New World hantaviruses. Am J Trop Med Hyg (2010) 2.92
Reverse genetics with a full-length infectious cDNA of severe acute respiratory syndrome coronavirus. Proc Natl Acad Sci U S A (2003) 2.82
Molecular Evidence of Sexual Transmission of Ebola Virus. N Engl J Med (2015) 2.71
Development of a new vaccine for the prevention of Lassa fever. PLoS Med (2005) 2.71
Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo. Proc Natl Acad Sci U S A (2010) 2.69
Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells. Am J Pathol (2003) 2.66
Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. PLoS Pathog (2007) 2.64
Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med (2006) 2.64
Evaluation of perceived threat differences posed by filovirus variants. Biosecur Bioterror (2011) 2.62
Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates. J Virol (2008) 2.58
Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic fever. J Infect Dis (2007) 2.44
A broad-spectrum antiviral targeting entry of enveloped viruses. Proc Natl Acad Sci U S A (2010) 2.41
Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus. J Virol (2009) 2.41
Virulence differences between monkeypox virus isolates from West Africa and the Congo basin. Virology (2005) 2.36
Exploring the potential of variola virus infection of cynomolgus macaques as a model for human smallpox. Proc Natl Acad Sci U S A (2004) 2.36
Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. Vaccine (2008) 2.33
Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections. Antiviral Res (2003) 2.31
Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody. J Virol (2002) 2.31
Evaluation in nonhuman primates of vaccines against Ebola virus. Emerg Infect Dis (2002) 2.26
Generation of eGFP expressing recombinant Zaire ebolavirus for analysis of early pathogenesis events and high-throughput antiviral drug screening. Virology (2005) 2.25
Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference. J Infect Dis (2006) 2.19
Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus Species. PLoS Pathog (2010) 2.18
Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog (2008) 2.10
Marburg virus Angola infection of rhesus macaques: pathogenesis and treatment with recombinant nematode anticoagulant protein c2. J Infect Dis (2007) 2.09
Proinflammatory response during Ebola virus infection of primate models: possible involvement of the tumor necrosis factor receptor superfamily. Immunol Lett (2002) 2.06
Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses. J Virol (2011) 1.99
The host response to smallpox: analysis of the gene expression program in peripheral blood cells in a nonhuman primate model. Proc Natl Acad Sci U S A (2004) 1.85
Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine. J Virol (2006) 1.85
CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates. Nat Med (2011) 1.83
Smallpox and pan-orthopox virus detection by real-time 3'-minor groove binder TaqMan assays on the roche LightCycler and the Cepheid smart Cycler platforms. J Clin Microbiol (2004) 1.77
Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. Proc Natl Acad Sci U S A (2007) 1.76
Dissecting interferon-induced transcriptional programs in human peripheral blood cells. PLoS One (2010) 1.73
Framework for leadership and training of Biosafety Level 4 laboratory workers. Emerg Infect Dis (2008) 1.66
Interferon-alpha initiates type 1 diabetes in nonobese diabetic mice. Proc Natl Acad Sci U S A (2008) 1.66
Management of accidental exposure to Ebola virus in the biosafety level 4 laboratory, Hamburg, Germany. J Infect Dis (2011) 1.62
FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection. Sci Transl Med (2013) 1.62
Virus nomenclature below the species level: a standardized nomenclature for natural variants of viruses assigned to the family Filoviridae. Arch Virol (2012) 1.59
Generation of Marburg virus-like particles by co-expression of glycoprotein and matrix protein. FEMS Immunol Med Microbiol (2004) 1.58
BAK alters neuronal excitability and can switch from anti- to pro-death function during postnatal development. Dev Cell (2003) 1.56
Depletion of peripheral blood T lymphocytes and NK cells during the course of ebola hemorrhagic Fever in cynomolgus macaques. Viral Immunol (2004) 1.55
Early days: genomics and human responses to infection. Curr Opin Microbiol (2006) 1.54
Ebola hemorrhagic fever: evaluation of passive immunotherapy in nonhuman primates. J Infect Dis (2007) 1.53
Ebola virus: new insights into disease aetiopathology and possible therapeutic interventions. Expert Rev Mol Med (2004) 1.52
Pathologic findings associated with delayed death in nonhuman primates experimentally infected with Zaire Ebola virus. J Infect Dis (2007) 1.52
Characterization of wild-type and cidofovir-resistant strains of camelpox, cowpox, monkeypox, and vaccinia viruses. Antimicrob Agents Chemother (2002) 1.49
Trigger events: enviroclimatic coupling of Ebola hemorrhagic fever outbreaks. Am J Trop Med Hyg (2004) 1.45
ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification. Antimicrob Agents Chemother (2009) 1.45
In vitro and in vivo characterization of recombinant Ebola viruses expressing enhanced green fluorescent protein. J Infect Dis (2007) 1.43
Postexposure treatment of Marburg virus infection. Emerg Infect Dis (2010) 1.43
Cynomolgus macaque as an animal model for severe acute respiratory syndrome. PLoS Med (2006) 1.40
Comparative analysis of viral gene expression programs during poxvirus infection: a transcriptional map of the vaccinia and monkeypox genomes. PLoS One (2008) 1.37
MassTag polymerase chain reaction for differential diagnosis of viral hemorrhagic fever. Emerg Infect Dis (2006) 1.35
Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates. PLoS Negl Trop Dis (2012) 1.32
Real-time PCR assay to detect smallpox virus. J Clin Microbiol (2003) 1.32
Capacity building permitting comprehensive monitoring of a severe case of Lassa hemorrhagic fever in Sierra Leone with a positive outcome: case report. Virol J (2011) 1.29
Ebola virus genome plasticity as a marker of its passaging history: a comparison of in vitro passaging to non-human primate infection. PLoS One (2012) 1.28
The pathogenesis of Rift Valley fever virus in the mouse model. Virology (2010) 1.28
Interferon-β therapy prolongs survival in rhesus macaque models of Ebola and Marburg hemorrhagic fever. J Infect Dis (2012) 1.27
Clinical management of filovirus-infected patients. Viruses (2012) 1.26
No model of clinical education for physiotherapy students is superior to another: a systematic review. Aust J Physiother (2007) 1.26
Comparative analysis of monkeypox virus infection of cynomolgus macaques by the intravenous or intrabronchial inoculation route. J Virol (2010) 1.25
Minigenomes, transcription and replication competent virus-like particles and beyond: reverse genetics systems for filoviruses and other negative stranded hemorrhagic fever viruses. Antiviral Res (2011) 1.24
Severe encephalitis in cynomolgus macaques exposed to aerosolized Eastern equine encephalitis virus. J Infect Dis (2007) 1.22